BioTime Appoints Co-CEO
This article was originally published in Scrip
BioTime, Inc., a company focusing on pluripotent stem cell technology, has appointed Adi Mohanty Co-CEO to serve with Michael D. West. Since 2014, Mohanty has been BioTime's chief operating officer and will now lead the company's advanced clinical development programs and commercialization strategies. Before BioTime, Mohanty was at Shire Plc. for 11 years where he most recently was president, head of the regenerative medicine business and previously he was also head of Shire's global franchise portfolio of biologic products for rare diseases. Prior to this, Mohanty held various management positions at Transkaryotic Therapies, Inc. (acquired by Shire) and general management, engineering and manufacturing positions at Baxter Bioscience (now Baxalta).
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.